Skin Care Regimen for Improving Photoaging Signs on the Face

September 16, 2024 updated by: Goldman, Butterwick, Fitzpatrick and Groff

A Prospective, Placebo-controlled, Double-blinded, Randomized Clinical Trial Evaluating the Efficacy and Tolerability of Pre and Post Care Skincare Regimen Paired With 1927nm Diode Fractional Laser for Photodamage on the Face

Compare the effectiveness of laser treatment using CE Ferulic versus vehicle pre/post laser.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Evaluate the efficacy and tolerability of a Skinceuticals CE Ferulic® when used once daily over the course of 14 weeks with 2-week pre-treatment period and 12-week treatment period in pairing with two pre-elected laser treatments with 1927nm non-ablative fractional diode laser treatment for improving skin photoaging signs on the face.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • California
      • San Diego, California, United States, 92121
        • West Dermatology Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adult males and females aged 30-70 years (Fitzpatrick I-IV 30-65 years, Fitzpatrick V-VI 30-70 years)
  • Fitzpatrick skin types I-VI
  • Subjects in good general health based on investigator's judgment and medical history
  • Must be willing to give and sign an informed consent form and photographic release form
  • Must be willing to have examinations of face and digital photographs performed of the face
  • Physician evaluator classifying the subject as mild to moderate (Score 3-6) on the modified Griffiths 10-Point Scale for the face.
  • The subject must be planning to undergo fractional non-ablative laser resurfacing to the face and bilateral postauricular area and be willing to comply with study protocol and complete the entire course of the study.
  • Subjects using any treatment skincare products (per investigator discretion) must discontinue use of these products four weeks before the start of participating in this clinical study and for the duration of the study.
  • Male subjects with facial hair must be willing to shave prior to every visit.
  • Must be willing to maintain usual sun exposure
  • Subject agrees to avoid tanning or use of sunless tanner during the entire course of the study
  • Negative urine pregnancy test result at the time of study entry (if applicable)
  • For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.
  • A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation.
  • Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g., condoms and spermicide), abstinence, and/or vasectomy of partner with a documented second acceptable method of birth control, should the subject become sexually active.
  • Must be willing to comply with study treatments and complete the entire course of the study

Exclusion Criteria:

  • Energy-based device (i.e., radiofrequency device treatments, microfocused ultrasound device or other ultrasound-based device treatments, laser and light-based device treatments, microneedling) treatment in the treatment area in the last 6 months
  • Chemical peel or microdermabrasion of the face within 60 days prior to enrollment in the study
  • Dermal fillers, biostimulators, or neurotoxins treatments of the face during the 6-month period before the study period or planning to undergo during the study period
  • Surgery (i.e., face lift, eyebrow lift, neck lift or lower rhytidectomy, liposuction to the neck and/or submentum, etc.) during the 12-month period before study treatment
  • Any investigational treatment for improvement of skin quality and/or photodamage of facial skin during the 6-month period before the study treatment
  • Use of topical steroids, tretinoin, adapalene, tazarotene, hydroquinone, imiquimod, 5-fluorouracil, ingenol mebutate, concentrated hydrogen peroxide, diclofenac, or photodynamic therapy (PDT) to the face within the previous 4 weeks
  • Subjects must not currently be taking isotretinoin (Accutane).
  • Creams/cosmeceuticals and/or home therapies to prevent or treat photodamage, uneven skin pigmentation, excessive erythema (redness), fine lines/wrinkles, skin laxity and/or pore size during the 4-week period before study treatment
  • Subjects with scarring in the treatment areas
  • Subjects with tattoos in the treatment areas
  • Subjects with a significant history or current evidence of a medical, psychological, or other disorder that, in the investigator's opinion, would preclude enrollment into the study
  • Subjects with a history of or presence of any skin condition/disease (including but not limited to any visible rash, atopic dermatitis, psoriasis, actinic keratoses, keratinocyte carcinoma, melanoma, etc.) in the treatment area that might interfere with the diagnosis or evaluation of study parameters
  • Skin with open wounds, excessively sensitive skin, neurotic excoriations, dermatitis or inflammatory rosacea in the treatment area
  • History of keloid or hypertrophic scarring
  • Subjects with an active bacterial, viral, or fungal infection of the treatment areas or systemic infection
  • Subjects who spray tanned or used sunless tanners in the treatment areas four (4) weeks prior to study treatment
  • History of lidocaine and/or tetracaine sensitivity deemed by the investigator to preclude the subject from enrolling into the study
  • Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study
  • Subjects must not have a compromised ability for wound healing, such as:

malnutrition, steroid use, history of collagen vascular disease (e.g., lupus, scleroderma), atopic dermatitis, or immunologic abnormalities such as vitiligo.

  • Subjects planning any cosmetic procedure to the treatment areas during the study period, other than the treatment that will be performed by the investigator
  • Presence of incompletely healed wound(s) in the treatment area
  • Subjects who are on an immunosuppressant or have an autoimmune condition
  • Female subjects who are pregnant, planning a pregnancy, or breast feeding during the study
  • Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group A
Subjects who will receive two treatments with 1927nm (Clear and Brilliant Perméa®) non-ablative fractional diode laser for rejuvenation of photodamaged skin of the face in pairing with Skinceuticals CE Ferulic
Drug: CE Ferulic
CE Ferulic serum regimen combined with laser treatment
Device: 1927nm (Clear and Brilliant Perméa®)
non-ablative fractional diode laser
Sham Comparator: Group B
Subjects who will receive two treatments with 1927nm (Clear and Brilliant Perméa®) non-ablative fractional diode laser for rejuvenation of photodamaged skin of the face in pairing with vehicle serum
Device: 1927nm (Clear and Brilliant Perméa®)
non-ablative fractional diode laser
Drug: Sham Comparator
Vehicle serum regimen combined with laser treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Global Fine Lines
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

Score 0 thru 9

Score 0= No fine lines present; skin looks completely smooth Score 9= Numerous, many fine lines densely packed together in the treatment area
Screening, Baseline, Day 28, Day 56, Day 84
Overall Hyperpigmentation/ Discoloration
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

Score 0 thru 9

Score 0= No hyperpigmentation Score 9= Significant hyperpigmentation, numerous spots, uneven skin tone
Screening, Baseline, Day 28, Day 56, Day 84
Skin Tone Evenness
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

Score 0 thru 9

Score 0= Very even tone Score 9= Uneven, discolored appearance (brown and/or red colors)
Screening, Baseline, Day 28, Day 56, Day 84
Skin Elasticity
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

Score 0 thru 9

Score 0= Skin feels toned, dense Score 9= Skin feels pliable, thin and non-resilient
Screening, Baseline, Day 28, Day 56, Day 84
Skin Firmness
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

Score 0 thru 9

Score 0= Firm, tight feeling skin Score 9= Loose, lax feeling skin
Screening, Baseline, Day 28, Day 56, Day 84
Skin Radiance/ Brightness
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

Score 0 thru 9

Score 0= Very radiant, luminous or glowing appearance Score 9= Very dull/ matte and/or sallow skin appearance
Screening, Baseline, Day 28, Day 56, Day 84
Skin Texture Smoothness
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

Score 0 thru 9

Score 0= Very smooth, even-looking skin texture, no roughness Score 9= Very rough, pronounced, extensive visible skin roughness
Screening, Baseline, Day 28, Day 56, Day 84
Global Wrinkles
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

Score 0 thru 9

Score 0= No wrinkles present, no visible deep, wide and long wrinkles, skin looks smooth Score 9= Numerous wrinkles, deep, wide and long, densely packed together in the treatment area
Screening, Baseline, Day 28, Day 56, Day 84

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tolerability Assessment
Time Frame: Baseline, Day 28

Stinging/Burning:

None No stinging/burning of the treatment area Mild Slight, but definite burning of the treatment area Moderate Definite stinging/burning of the treatment area Severe Marked stinging/burning of the treatment area

Itching:

None No itching of the treatment area Mild Slight, but definite itching of the treatment area Moderate Definite itching of the treatment area Severe Marked itching of the treatment area

Rash:

None No new rash over the treatment area Mild New rash covering some of the treatment area Moderate New rash covering much of the treatment area Severe New rash covering the entirety of the treatment area

Tightness:

None No tightness of the treatment area Mild Slight, but definite tightness of the treatment area Moderate Definite tightness of the treatment area Severe Marked tightness of the treatment area
Baseline, Day 28
Dermatology Quality of Life Index (Page 1)
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

  1. Over the last week, how itchy, sore, painful or stinging has your skin been:

    Very Much A lot A little Not at all

  2. Over the last week, how embarrassed or self-conscious have you been because of your skin:

    Very Much A lot A little Not at all

  3. Over the last week, how much has your skin interfered with you going shopping or looking after your home or garden:

    Very Much A lot A little Not at all

  4. Over the last week, how much has your skin influenced the clothes you wear:

    Very Much A lot A little Not at all

  5. Over the last week, how itchy, sore, painful or stinging has your skin been:

    Very Much A lot A little Not at all

  6. Over the last week, how much has your skin made it difficult for you to do any sport:

Very Much A lot A little Not at all
Screening, Baseline, Day 28, Day 56, Day 84
Dermatology Quality of Life Index (Page 2)
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

7.Over the last week, has your skin prevented you from working or studying: Yes or No 7a. If "no", over the last week how much has your skin been a problem at work or studying: Very Much A lot A little Not at all

8.Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives: Very Much A lot A little Not at all

9.Over the last week, how much has your skin caused any sexual difficulties: Very Much A lot A little Not at all

10.Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time: Very Much A lot A little Not at all
Screening, Baseline, Day 28, Day 56, Day 84
Subject Self-Assessment Questionnaire (Page 1)
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

  1. Skin feels more comfortable:

    Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

  2. Skin appears younger looking:

    Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

  3. Skin appears healthier:

    Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

  4. Skin looks renewed/ revitalized:

    Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

  5. Skin looks firmer:

    Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

  6. Skin feels elastic:

    Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

  7. Redness looks reduced:

Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly
Screening, Baseline, Day 28, Day 56, Day 84
Subject Self-Assessment Questionnaire (Page 2)
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

8. With the product I'm more satisfied with the procedure results: Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

9. The product reduced the downtime of the procedure or makes the downtime more acceptable: Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

10. The product improves the outcome of the procedure: Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

11. With this product, I would feel more confident to do another procedure: Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

12. I would recommend this product post-procedure: Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly
Screening, Baseline, Day 28, Day 56, Day 84
Subject Self-Assessment Questionnaire (Page 3)
Time Frame: Screening, Baseline, Day 28, Day 56, Day 84

13. It's the best post-procedure care I've ever used (if relevant) : Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

14. It is something I would use after future laser treatments: Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

15. The product has a pleasant texture: Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

16. The product absorbs quickly in to the skin: Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly

17. It is a product I would recommend to others: Agree Strongly Agree Neither agree nor disagree Disagree Disagree Strongly
Screening, Baseline, Day 28, Day 56, Day 84

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Goldman, Butterwick, Fitzpatrick and Groff

Collaborators

L'Oreal

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 27, 2024

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

February 28, 2025

Study Registration Dates

First Submitted

September 12, 2024

First Submitted That Met QC Criteria

September 16, 2024

First Posted (Estimated)

September 19, 2024

Study Record Updates

Last Update Posted (Estimated)

September 19, 2024

Last Update Submitted That Met QC Criteria

September 16, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Skinceuticals CE Ferulic 2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Improve Photoaging Signs

Clinical Trials on CE Ferulic

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe